{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:54:13Z","timestamp":1790812453814,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Acute promyelocytic leukaemia differentiation syndrome (APL DS) is seen when patients with APL are treated with all\u2010<jats:italic>trans<\/jats:italic> retinoic acid (ATRA) and\/or arsenic trioxide (ATO). Presenting symptoms are varied but frequently include dyspnoea, unexplained fever, weight gain &gt;5\u00a0kg, unexplained hypotension, acute renal failure and a chest radiograph demonstrating pulmonary infiltrates or pleural or pericardial effusion. Immediate treatment with steroids at the first clinical suspicion is recommended and ATRA\/ATO should be stopped in severe cases or if there is no response to treatment. The utility of steroid prophylaxis in order to prevent APL DS is less certain. Here we provide a detailed review of the pathogenesis, clinical signs and symptoms as well as management and prophylaxis strategies of APL DS.<\/jats:p>","DOI":"10.1111\/bjh.16151","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T01:39:14Z","timestamp":1565746754000},"page":"157-162","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["Differentiation syndrome in acute promyelocytic leukaemia"],"prefix":"10.1111","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1299-5901","authenticated-orcid":false,"given":"Maximilian","family":"Stahl","sequence":"first","affiliation":[{"name":"Leukemia Service, Department of Medicine Memorial Sloan Kettering Cancer Center New York NY USA"},{"name":"Weill Cornell Medical College New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[{"name":"Leukemia Service, Department of Medicine Memorial Sloan Kettering Cancer Center New York NY USA"},{"name":"Weill Cornell Medical College New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.8.2712"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.11.3264.3264"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-4-292"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410746"},{"key":"e_1_2_9_6_1","first-page":"5017","article-title":"Weight gain during induction therapy of acute promyelocytic leukemia patients: a preventable problem","volume":"130","author":"Kota V.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.7.2747"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276196"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300874"},{"key":"e_1_2_9_10_1","first-page":"1014","article-title":"Molecular remission in PML\/RAR alpha\u2010positive acute promyelocytic leukemia by combined all\u2010trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano\u2010Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups","volume":"90","author":"Mandelli F.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.4911029.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168617"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.158.4.9709085"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2001.16.3.218"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6130"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-512640"},{"key":"e_1_2_9_17_1","first-page":"3015","article-title":"A modified AIDA protocol with anthracycline\u2010based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML\/RARalpha\u2010positive acute promyelocytic leukemia","volume":"94","author":"Sanz M.A.","year":"1999","journal-title":"PETHEMA group. Blood"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-159632"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-266007"},{"key":"e_1_2_9_20_1","first-page":"95","article-title":"All\u2010trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia","volume":"10","author":"Seale J.","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_9_21_1","first-page":"90","article-title":"Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome","volume":"95","author":"Tallman M.S.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.11.3843.bloodjournal84113843"},{"key":"e_1_2_9_23_1","first-page":"774","article-title":"Reduction of pulmonary toxicity by prednisolone prophylaxis during all\u2010trans retinoic acid treatment of acute promyelocytic leukemia","volume":"9","author":"Wiley J.S.","year":"1995","journal-title":"Australian Leukaemia Study Group. Leukemia"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.16151","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16151","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16151","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T07:58:57Z","timestamp":1693209537000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1111\/bjh.16151"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16151","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]},"assertion":[{"value":"2019-08-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}